Moore to follow Cummins and Westbrook out of Cyberonics?:
This article was originally published in Clinica
A major shareholder in vagus nerve stimulation device make Cyberonics (Houston, Texas) has demanded the removal of Kevin Moore as director, and is seeking his return of fees and stock options. Metropolitan Capital Advisors (MCA) has given the company ten days to take the action against Mr Moore, who, it maintains, was not lawfully a member of the board, having not stood for election at the company's 2004 and 2005 AGM. MCA representatives also criticised the appointment of Tony Coelho as chairman (see Clinica No 1233, p 17), saying he had a role in the granting of options, with "serious consequences for Cyberonics".
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.